Altered morphology and immunohistochemical characteristics in metastatic malignant melanoma after therapy with vemurafenib

Matthew R. Powell, Daniel J Sheehan, Daniel T Kleven

Research output: Contribution to journalArticle

Abstract

Metastatic melanoma is traditionally diagnosed using classic morphologic features in addition to immunohistochemical studies. The authors report a case of metastatic malignant melanoma where both morphology and immunohistochemistry were altered after treatment. This 51-year-old patient presented with metastatic melanoma to the brain and axilla. Initially, both metastases showed classic morphology and diffuse staining with the pan-melanoma antibody cocktail. This cocktail is a combination of 3 antibodies commonly used to diagnose melanocytic neoplasms: Melan-A (MART-1), tyrosinase, and HMB-45. In combination, the cocktail is highly sensitive for detecting melanocytic neoplasms and is commonly used to diagnose metastatic melanoma. Her tumor was positive for the BRAF 1799T>A (V600E) mutation, and she was treated with BRAF inhibitor therapy (vemurafenib). However, the axillary tumor recurred after treatment with vemurafenib. The recurrent tumor showed a markedly different morphology and complete loss of staining with the pan-melanoma antibody cocktail. This loss of staining accompanied by the change in morphology was an observation not previously documented after therapy with vemurafenib. This case demonstrates a potential pitfall in the diagnosis of metastatic or recurrent malignant melanoma.

Original languageEnglish (US)
Pages (from-to)e137-e139
JournalAmerican Journal of Dermatopathology
Volume38
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Melanoma
Neoplasms
Staining and Labeling
Therapeutics
Antibodies
MART-1 Antigen
Axilla
Monophenol Monooxygenase
PLX4032
Immunohistochemistry
Observation
Neoplasm Metastasis
Mutation
Brain

Keywords

  • BRAF inhibitor therapy
  • changes in recurrent metastatic malignant melanoma
  • malignant melanoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Dermatology

Cite this

Altered morphology and immunohistochemical characteristics in metastatic malignant melanoma after therapy with vemurafenib. / Powell, Matthew R.; Sheehan, Daniel J; Kleven, Daniel T.

In: American Journal of Dermatopathology, Vol. 38, No. 9, 01.09.2016, p. e137-e139.

Research output: Contribution to journalArticle

@article{d1e666febe0c4d609ab13d4983525f26,
title = "Altered morphology and immunohistochemical characteristics in metastatic malignant melanoma after therapy with vemurafenib",
abstract = "Metastatic melanoma is traditionally diagnosed using classic morphologic features in addition to immunohistochemical studies. The authors report a case of metastatic malignant melanoma where both morphology and immunohistochemistry were altered after treatment. This 51-year-old patient presented with metastatic melanoma to the brain and axilla. Initially, both metastases showed classic morphology and diffuse staining with the pan-melanoma antibody cocktail. This cocktail is a combination of 3 antibodies commonly used to diagnose melanocytic neoplasms: Melan-A (MART-1), tyrosinase, and HMB-45. In combination, the cocktail is highly sensitive for detecting melanocytic neoplasms and is commonly used to diagnose metastatic melanoma. Her tumor was positive for the BRAF 1799T>A (V600E) mutation, and she was treated with BRAF inhibitor therapy (vemurafenib). However, the axillary tumor recurred after treatment with vemurafenib. The recurrent tumor showed a markedly different morphology and complete loss of staining with the pan-melanoma antibody cocktail. This loss of staining accompanied by the change in morphology was an observation not previously documented after therapy with vemurafenib. This case demonstrates a potential pitfall in the diagnosis of metastatic or recurrent malignant melanoma.",
keywords = "BRAF inhibitor therapy, changes in recurrent metastatic malignant melanoma, malignant melanoma",
author = "Powell, {Matthew R.} and Sheehan, {Daniel J} and Kleven, {Daniel T}",
year = "2016",
month = "9",
day = "1",
doi = "10.1097/DAD.0000000000000619",
language = "English (US)",
volume = "38",
pages = "e137--e139",
journal = "American Journal of Dermatopathology",
issn = "0193-1091",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Altered morphology and immunohistochemical characteristics in metastatic malignant melanoma after therapy with vemurafenib

AU - Powell, Matthew R.

AU - Sheehan, Daniel J

AU - Kleven, Daniel T

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Metastatic melanoma is traditionally diagnosed using classic morphologic features in addition to immunohistochemical studies. The authors report a case of metastatic malignant melanoma where both morphology and immunohistochemistry were altered after treatment. This 51-year-old patient presented with metastatic melanoma to the brain and axilla. Initially, both metastases showed classic morphology and diffuse staining with the pan-melanoma antibody cocktail. This cocktail is a combination of 3 antibodies commonly used to diagnose melanocytic neoplasms: Melan-A (MART-1), tyrosinase, and HMB-45. In combination, the cocktail is highly sensitive for detecting melanocytic neoplasms and is commonly used to diagnose metastatic melanoma. Her tumor was positive for the BRAF 1799T>A (V600E) mutation, and she was treated with BRAF inhibitor therapy (vemurafenib). However, the axillary tumor recurred after treatment with vemurafenib. The recurrent tumor showed a markedly different morphology and complete loss of staining with the pan-melanoma antibody cocktail. This loss of staining accompanied by the change in morphology was an observation not previously documented after therapy with vemurafenib. This case demonstrates a potential pitfall in the diagnosis of metastatic or recurrent malignant melanoma.

AB - Metastatic melanoma is traditionally diagnosed using classic morphologic features in addition to immunohistochemical studies. The authors report a case of metastatic malignant melanoma where both morphology and immunohistochemistry were altered after treatment. This 51-year-old patient presented with metastatic melanoma to the brain and axilla. Initially, both metastases showed classic morphology and diffuse staining with the pan-melanoma antibody cocktail. This cocktail is a combination of 3 antibodies commonly used to diagnose melanocytic neoplasms: Melan-A (MART-1), tyrosinase, and HMB-45. In combination, the cocktail is highly sensitive for detecting melanocytic neoplasms and is commonly used to diagnose metastatic melanoma. Her tumor was positive for the BRAF 1799T>A (V600E) mutation, and she was treated with BRAF inhibitor therapy (vemurafenib). However, the axillary tumor recurred after treatment with vemurafenib. The recurrent tumor showed a markedly different morphology and complete loss of staining with the pan-melanoma antibody cocktail. This loss of staining accompanied by the change in morphology was an observation not previously documented after therapy with vemurafenib. This case demonstrates a potential pitfall in the diagnosis of metastatic or recurrent malignant melanoma.

KW - BRAF inhibitor therapy

KW - changes in recurrent metastatic malignant melanoma

KW - malignant melanoma

UR - http://www.scopus.com/inward/record.url?scp=84983395232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983395232&partnerID=8YFLogxK

U2 - 10.1097/DAD.0000000000000619

DO - 10.1097/DAD.0000000000000619

M3 - Article

VL - 38

SP - e137-e139

JO - American Journal of Dermatopathology

JF - American Journal of Dermatopathology

SN - 0193-1091

IS - 9

ER -